Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient
Eosinophilic myocarditis (EM) is a rare cause of heart failure, with high in-hospital mortality associated with fulminant disease. A 61-year-old female transplant recipient was diagnosed with COVID-19 after presenting with 2 days of constitutional symptoms. She developed acute heart failure from EM. After an initial response to inotropic support and corticosteroids, she had a relapse with de novo peripheral eosinophilia which responded to further eosinophilic myocarditis management and the addition of mepolizumab. Although there have been reports after COVID-19 vaccination, association with active SARS-CoV-2 infection is rare. This paper reports, for the first time, the case of a heart transplant recipient with EM after COVID-19.
Authors
- Jacob Colin Jentzer (ORCID: https://orcid.org/0000-0002-6366-2859)
- Adrian daSilva‐deAbreu (ORCID: https://orcid.org/0000-0002-6739-5946)
- Nandan S. Anavekar
- Atta Behfar (ORCID: https://orcid.org/0000-0003-3775-5784)
- Leslie T. Cooper (ORCID: https://orcid.org/0000-0003-1002-3313)
- Sara S. Inglis (ORCID: https://orcid.org/0000-0003-3200-3575)
- Shannon M. Dunlay (ORCID: https://orcid.org/0000-0001-5145-7420)
- Francisco B. Alexandrino (ORCID: https://orcid.org/0009-0000-5120-5581)
- Anshul Gupta (ORCID: https://orcid.org/0000-0003-3228-5250)
- Marie Christine Aubry
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.jaccas.2024.102527
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00